Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (Q37961390)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study |
scientific article |
Statements
1 reference
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (English)
1 reference
John D Hainsworth
1 reference
Marianne E Pavel
1 reference
Eric Baudin
1 reference
Dieter Hörsch
1 reference
Robert E Winkler
1 reference
Judith Klimovsky
1 reference
David Lebwohl
1 reference
Valentine Jehl
1 reference
Edward M Wolin
1 reference
Kjell Öberg
1 reference
Eric Van Cutsem
1 reference
James C Yao
1 reference
RADIANT-2 Study Group
1 reference
25 November 2011
1 reference
1 reference
378
1 reference
9808
1 reference
2005-2012
1 reference
Identifiers
1 reference
1 reference